Hormonal therapies used for prostate cancer may protect against COVID-19

According to research conducted in the autonomous region of Veneto in northeastern Italy, androgen deprivation therapy recipients with prostate cancer have a milder course of COVID-19 disease caused by the novel coronavirus; a lower risk of serious complications was found in these patients. SARS-CoV-2 infection was confirmed by positive tests in the 9280 patients included in the study, which was published online in Annals of Oncology, one of the leading scientific journals in oncology.
There were 4532 men in this patient group; 430 (9.5%) had some type of cancer and 118 (2.6%) had prostate cancer.
Considering only the male population of Veneto (2.4 million men), 0.2% of those without cancer and 0.3% of cancer patients tested positive for SARS-CoV-2, respectively.
Overall, the study found that cancer patients had more severe COVID-19 symptoms (signs) than patients without cancer. Of all male coronavirus patients, 47% were hospitalized and 6.9% died, whereas 67.9% of male cancer patients were hospitalized and 17.4% died.
However, when prostate cancer patients were divided according to whether they received androgen (male sex organ) deprivation therapy, patients receiving hormonal therapy were found to have an even lower risk of infection than people without cancer. Strikingly, only 4 of the 5273 patients receiving hormone deprivation therapy in Veneto developed SARS-CoV-2 infection, and none of these patients died.
What is the possible biological link between hormone deprivation therapy and COVID-19?
There is a biologically plausible idea for the link between androgen deprivation and COVID-19. To enter the cell, SARS-CoV-2 binds to the ACE2 receptor. After binding, an enzyme called TMPRSS2 cuts the spike protein from the virus, allowing it to fuse with the cell membrane. The hormone testosterone stimulates TMPRSS2 production, and in many prostate cancers this enzyme increases tumor growth. Hormone deprivation therapy is one of the main treatments for prostate cancer to lower testosterone levels.

Figure explanation: We have a group of enzymes that help the virus's attachment arm, the spike protein (S protein), enter the cell by binding to ACE2 receptors on our cells: Serine Protease Enzymes. The specific group that helps SARS-COV-2 is called “Serine Protease TMPRSS2”. TMPRSS2, which basically acts as a cleaving enzyme, breaks down the viral S protein, allowing the virus and host cell membranes to fuse. The identification of this enzyme and detailed elucidation of the entry mechanism in recent studies led scientists to ask new questions: “Which of our cells have both the ACE2 receptor and the TMPRSS2 enzyme?”, “If we block the function of the TMPRSS2 enzyme, can we prevent the virus from entering our cells?”
- Related topic: Targeting the BEST SUPPORTING PLAYER (TMPRSS2) for COVID-19 treatment
Evidence shows that lung epithelial cells also express TMPRSS2. Treating lung cells with TMPRSS2 inhibitors reduces the ability of SARS-CoV-2 to enter the cell. Hypothetically, androgen deprivation drugs should reduce TMPRSS2 expression and prevent the virus from infecting lung cells.
Based on these findings, other researchers are planning a study in Sweden to test the effect of anti-androgen drugs on SARS-CoV-2 infection. The Swedish study will test one of the new-generation hormonal therapies for prostate cancer, enzalutamide. The study plans to administer enzalutamide for 5 days and then assess how many patients will need intensive care units.
Anti-androgen therapy is also thought to potentially help prevent COVID-19 disease in women. However, TMPRSS2 expression is weaker in women than in men (perhaps this is one of the reasons women are less likely to get COVID-19). Enzalutamide is also being tested in some breast cancer clinical trials. Seeing whether this hormone therapy works in both men and women could yield surprising results.
A United States-based clinical trial will test how effectively COVID-19 severity can be reduced with another hormone deprivation drug called degarelix. This phase-II trial will enroll 198 men who test positive for SARS-COV-2 and are hospitalized but not intubated (not connected to a ventilator in intensive care). Unlike the Swedish study, this study will exclude women. The reason given is that estrogen, known as the female sex hormone, may suppress TMPRSS2 expression; therefore, lowering estrogen levels could increase TMPRSS2 expression and worsen COVID-19... Future studies will reveal more clearly the relationship between COVID-19 treatment and our hormones.
Sources
2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020.
3. Baratchian M, McManus J, Berk M, et al. No evidence that androgen regulation of pulmonary TMPRSS2 explains sex-discordant COVID-19 outcomes [preprinted online April 21, 2020.
4. Clinicaltrials.gov. Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH). NCT04397718. https://clinicaltrials.gov/ct2/show/NCT04397718. Accessed June 3, 2020.
5. Caroline Seydel
Androgen Deprivation Therapy May Protect Against COVID-19 in Prostate Cancer.
https://www.cancertherapyadvisor.com/home/cancer-topics/prostate-cancer/covid19-coronavirus-prostate-cancer-adt-therapy-protect-treatment/2/ 18 June 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.